Table 3. Proportion of Patients Undergoing Chemotherapy With or Without Axillary Lymph Node Dissection (ALND).
| Group | Arm A: ALND | Arm B: No ALND | Difference (95% CI)a |
|---|---|---|---|
| Upfront surgery setting, No./total No. (%) | |||
| All subtypes | 101/169 (59.8) | 92/166 (55.4) | 4.3% (−6.8% to 16%) |
| HR+/ERBB2− | 91/151 (60.3) | 81/145 (55.9) | 4.4% (−7.5% to 16%) |
| HR+/ERBB2− Premenopausal | 36/47 (76.6) | 28/37 (75.7) | 0.9% (−18% to 20%) |
| HR+/ERBB2− Postmenopausal | 55/104 (52.9) | 53/108 (49.1) | 3.8% (−11% to 18%) |
| Neoadjuvant chemotherapy,b No./total No. (%) | |||
| All subtypes | 24/77 (31.2) | 20/74 (27.0) | 4.1% (−12% to 20%) |
| HR+/ERBB2− | 5/41 (12.2) | 8/48 (16.7) | −4.5% (−21% to 12%) |
| HR+/ERBB2+ | 11/20 (55.0) | 7/12 (58.3) | −3.3% (−42% to 35%) |
| HR−/ERBB2− | 7/14 (50.0) | 4/12 (33.3) | 17% (−28% to 62%) |
| HR−/ERBB2+ | 0/1 (0) | 1/1 (100) | −100% (−100% to 0%) |
| Premenopausal | 11/27 (40.7) | 10/34 (29.4) | 11% (−16% to 39%) |
| Postmenopausal | 13/50 (26.0) | 10/40 (25.0) | 1% (−18% to 20%) |
Abbreviations: ERBB2−, Erb-B2 receptor tyrosine kinase 2 negative (formerly HER2 or HER2/neu); ERBB2+, Erb-B2 receptor tyrosine kinase 2 positive; HR−, hormone receptor negative; HR+, hormone receptor positive.
a
Difference in proportions.
b
Fourteen patients had other neoadjuvant therapy than chemotherapy.